| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2017/044 | ||
|---|---|---|---|
| Date of filing | 26/10/2017 | ||
| Notification of Application Published | 29/11/2017 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
ROCHE GLYCART AG Wagistrasse 18 8952 Schlieren-Zuerich SWITZERLAND |
||
| Patent Number | 2464382 | ||
| Title of Invention | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE | ||
| Date of Expiry of Patent | 11/08/2030 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Obinutuzumab in combination with Bendamustine | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/14/937 | ||
| Authorisation Date | 13/06/2016 | ||
| Identity of Product Authorised | Gazyvaro-Obinutuzumab in combination with Bendamustine | ||
| Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||
| Renewal Fees | |||
| 31/10/2017 | Request for grant a Supplementary Protection Certificate filed on 26/10/2017, numbered 2017/044. | ||
| 08/12/2020 | Request for grant of Supplementary Protection Certification No. 2017/044 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
| 24/03/2021 | Written grounds of decision issued on 19 January 2021. | ||